anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a polyacrylic acid-cystamine dihydrochloride-vitamin E succinate polymer. The polymer is formed by bridging vitamin E succinate onto the main chain polyacrylic acid through diamino group, and the structural formula of the polymer is disclosed as Formula (I). The polyacrylic acid-cystamine dihydrochloride-vitamin E succinate polymer is hydrophilic and is responsive to GSH reduction, and can be used as an excellent antineoplastic drug carrier. The preparation method is simple, and is mild in conditions. The used materials are novel, and have the advantages of lower critical micelle concentration, favorable biocompatibility and favorable biodegradability. The carrier material can be self-assembled to form a micelle in water, and can be used for increasing the solubility of water-insoluble drugs and improving the distribution in vivo.
Heart rate variability (HRV) is a sign of cardiac autonomic nervous system. Evaluation of HRV in pediatric ventricular septal defect (VSD) cases before and after transcatheter closure will enlighten us in terms of cardiac autonomic control.

Methods: 19 VSD cases treated with transcatheter closure method and 18 healthy children were enrolled in the study. 24 hours Holter rhythm monitorization was applied to all patients before closure of VSD and to the control group. In the patient group, Holter rhythm monitorization was repeated in the third months. HRV parameters were obtained from Cardio Scan Premier 12® program. Frequency domain (Total power, VLF, LF, HF, LF/HF ratio) and time domain analysis (SDNN, SDANN, SDNNi, pNN50, rMSSD) were applied.
One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
INTRODUCTION: Williams syndrome (WS) cases have been reported to have with 25-100 times greater increased risk of sudden cardiac death (SCD). SCD has been reported in cases without any evidence of structural cardiovascular anomalies. Wolff-Parkinson-White (WPW) syndrome is characterized by short PR interval and delta wave. Ventricular preexcitations can develop paroxysmal reentrant tachycardia through Kent bundle or less frequent atrial fibrillation and in some cases with accessory pathway effective refractory period (APERP) under 250 ms considered as risky and may lead to SCD. WS associated with WPW has not been reported before.
CASE REPORT: An 11-year-old male who had been followed up with WS was referred to pediatric cardiology outpatient clinic with the complaint of palpitation. Electrocardiographic examination showed short PR interval and delta wave in the ECG consistent with WPW. He underwent electrophysiological study (EPS). Basic measurements were performed, and APERP was found at 280 ms cycle atrial pacing. RF energy was delivered using a 4 mm tip nonirrigated radiofrequency (RF) ablation catheter where the best ventriculoatrial (VA) signals were received and the AP was abolished within few seconds.
DISCUSSION AND CONCLUSIONS: Although, WPW cases are usually asymptomatic or related to SVT, the risk of SCD should not be ignored. Thus, all patients with WPW deserve an EPS for assessing the AP conduction properties. Due to the increased risk of SCD in patients with WS compared to general population, in the presence of concomitant WPW, these patients should be evaluated with EPS even if they do not have symptoms.
FIELD: medicine.SUBSTANCE: proposed system and method contain the first database, which contains data related to a particular type of research. The data includes time consumption, and data associated with the use of resources associated with a particular type of research. The second database, which contains data on a group of patients. The mentioned data connects each patient from the group with a personalized list of researches that the patient must undergo. A planning unit that is functionally linked to the first database and the second database. Planning unit is made with an ability to define a research sequence schedule for each patient of a group based on a personalized list of patient research and data from the first database, to maximize the number of patients of this group that can be served per day while limiting the maximum total time for each patient's schedule. The sequence includes information related to the time and type of research. An input box for entering information about progress based on the progress of patients, which is checked against the schedule. The system is configured to adapt the schedule based on the input progress information when the schedule needs to be updated.EFFECT: group of inventions ensures maximization of the number of patients that can be served per day using the shortest intervals between studies, which allows to limit the total time for the schedule of each patient of the group.13 cl, 7 dwg
Safety and efficacy of REBINYN were evaluated in four clinical trials that included 43 PTPs and in one clinical trial that included 50 pediatric PUPs [see Adverse Reactions (6) and Clinical Studies (14)]. Twelve of these subjects were ≤ 6 years of age; 13 subjects were 7 to 12 years of age; and 18 subjects were 13 to 17 years of age. Pharmacokinetic parameters were evaluated for 28 of the pediatric PTPs who were treated with REBINYN 40 IU/kg [see Clinical Pharmacology (12.3)]. 

Body weight-adjusted clearance was observed to be higher for pediatric subjects than for adult subjects. However, in clinical trials, no dose adjustment was needed in pediatric subjects who received a fixed dose of 40 IU/kg every week for routine prophylaxis. 

Juvenile Animal Toxicity Data

A juvenile animal neurotoxicity study was conducted to evaluate the potential neurotoxicity of REBINYN when intravenously administered 120-1200 IU/kg/twice weekly in immature male rats from 3 to 13 weeks of age, followed by a 13-week treatment-free period. Accumulation of PEG was observed in the choroid plexus, pituitary, circumventricular organs, and the cranial motor neurons. PEG levels in these tissues increased with dose and dose duration (10 weeks) and remained detectable after the 13-week treatment-free period. Treatment-related PEG-positive vacuolated macrophages were observed in the pituitary. The accumulation of PEG was not associated with neurobehavioral changes, fertility, or functional effects.
PURPOSE:To obtain a new 4-alkylamino-substituted-pyrrolo[2,3-d]pyrimidine derivative useful for preventing and treating hypoxemia followed by respiratory diseases. CONSTITUTION:A compound of formula I [R1 is H, methyl, etc.; R<2> is aryl, 2-methylallyl, etc.; Z is 1-4C chain aliphatic hydrocarbon], e.g. 2-allylamino-4- chloro[2,3-d]pyrimidine. The compound of formula I is obtained by passing through a compound, etc., of formula IV obtained by treating a cyanoacetic acid ester of formula III used as a starting raw material with acetal of formula II under alkali condition and cyclizing the resultant compound using a guanidine in the presence of a strong alkali.
When human skin is exposed to ultraviolet radiation from the sun or via the use of solaria, it responds by increasing melanin levels within epidermal melanocytes. Ultraviolet light enhances the local production and release of alpha-melanocyte stimulating hormone (alpha-MSH), which results in increased melanin levels through a process known as melanogenesis. Melanin, in the form of eumelanin, is a photoprotective agent. The mechanisms proposed for photoprotection include, but are not limited to, the absorption and scattering of UV and visible radiation, free radical scavenging and quenching of UV light. There is also increasing evidence that melanogenesis represents a major antioxidant defence mechanism in melanocytes, neutralising the deleterious effects of free radicals and active oxygen species. Eumelanin acts as a neutral density filter and, unlike most sunscreens, reduces all wavelengths of light equally so that the photoprotection provided by epidermal melanin pigmentation is essentially independent of wavelength.

CUV1647 (\[Nle4-D-Phe7\]-alpha-MSH) is a potent and longer lasting analogue of alpha-MSH which stimulates the production of eumelanin in the skin without the specific cell damage that usually occurs when melanin production is stimulated by UV radiation.

Urticaria is one of the most common dermatological conditions with diverse clinical presentations and causes. Solar urticaria (SU) is a rare subset of physical urticaria, where symptoms are induced by direct exposure of the skin to sunlight. As little as 5 minutes of sun exposure can cause flares and whealing on exposed skin sites, accompanied by severe itching. The wavelengths of radiation causing the eruption (i.e. the action spectrum) are in the ultraviolet or visible light range. Initially described by Merklen in 1904, SU may have a very sudden and dramatic onset, and then rapidly disappear once the exposure ceases. A delayed form of SU has also been reported, although this is extremely rare. Information on the pathophysiology of SU is limited and symptoms are confined to areas of the body exposed to direct sunlight. The condition can be very distressing and severely impair the individual's ability to go outdoors and to tolerate indoor lighting. The standard therapy, i.e. oral antihistamines, is only partially effective and may provide little worthwhile relief of symptoms.

This pilot study is proposed to evaluate implants containing 16mg CUV1647 as a prophylactic treatment for patients with SU. The effectiveness of CUV1647 will be assessed by determining the minimum urticarial dose before and after treatment.
AIMS: Hepatocellular carcinoma (HCC) is a lead cause of cancer-related deaths. In the present study we investigated the role of Brahma-related gene 1 (BRG1), a chromatin remodeling protein, in HCC the pathogenesis focusing on identifying novel transcription targets.
METHODS AND MATERIALS: Hepatocellular carcinogenesis was modeled in mice by diethylnitrosamine (DEN). Cellular transcriptome was evaluated by RNA-seq.
RESULTS: Hepatocellular carcinoma was appreciably retarded in BRG1 knockout mice compared to wild type littermates. Transcriptomic analysis identified ATP Binding Cassette Subfamily C Member 3 (ABCC3) as a novel target of BRG1. BRG1 over-expression in BRG1low HCC cells (HEP1) up-regulated whereas BRG1 depletion in BRG1high HCC cells (SNU387) down-regulated ABCC3 expression. Importantly, BRG1 was detected to directly bind to the ABCC3 promoter to activate ABCC3 transcription. BRG1 over-expression in HEP1 cells promoted proliferation and migration, both of which were abrogated by ABCC3 silencing. On the contrary, BRG1 depletion in SNU387 cells decelerated proliferation and migration, both of which were rescued by ABCC3 over-expression. Importantly, high BRG1/ABCC3 expression predicted poor prognosis in HCC patients. Mechanistically, ABCC3 regulated hepatocellular carcinogenesis possibly by influencing lysosomal homeostasis.
SIGNIFICANCE: In conclusion, our data suggest that targeting BRG1 and its downstream target ABCC3 can be considered as a reasonable approach for the intervention of hepatocellular carcinoma.
PROBLEM TO BE SOLVED: To obtain the subject compact and readily administrable pharmaceutical preparation capable of achieving proper substained release and stably providing sufficient initial effects and sustained effects and having uniform and stable quality by including bezafibrate and a specific hydroxypropyl cellulose(HPC) therein. SOLUTION: This pharmaceutical preparation contains (A) bezafibrate and (B) an HPC having about 1 to about 5 cP, preferably about 1 to about 3 cP, more preferably 2.0-2.9 cP viscosity of a 2 wt.% aqueous solution at 20 deg.C. The content of the ingredient B is usually 0.01-0.5 pt.wt., preferably 0.05-0.4 pt.wt., more preferably 0.1-0.3 pt.wt. based on 1 pt.wt. of the ingredient A. An HPC having a viscosity different from that of the HPC, hydroxypropyl methyl cellulose or polyvinyl alcohol may be contained in addition to the HPC in the pharmaceutical preparation. The resultant pharmaceutical preparation is useful as a therapeutic agent for hyperlipemia.
The Vegetables for All project will create FFZs in low-income urban and peri-urban areas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will link vendors and farmers through market facilitators, support the uptake of digital solutions for vendors to access vegetables, and support district governments to improve market infrastructure. To encourage BoP parents of children 3-9 years to buy and consume more vegetables, the program will include a demand generation component.
The invention discloses an external-use medicine for treating damp toxin infectious diseases. The external-use medicine is prepared by proportionally mixing 4-8g of camphor, 4-8g of catechu, 10-20g of kudzu vine root, 4-8g of cinnabar, 1-2g of borneol, 1-2g of salicylic acid and 1-5g of benzoic acid and soaking in an alcohol solution. The external-use medicine is based on the theories of traditional Chinese and Western medicine, and traditional Chinese and Western medicines are integrated for the causes of diseases to better develop the double effects of detoxifying, clearing toxic substances and relieving itching. The disadvantages of treating the damp toxin infectious diseases with traditional Chinese or Western medicine in the past are changed; better curative effects of the medicine are developed. The external-use medicine has the treatment characteristics of quick acting and quick effect taking, easy use for patients, remarkable curative effect, complete curing and the like, and further is stable in curative effect, easily available in raw materials and free from toxic or side effects; the diseases are not prone to relapse. The invention also discloses a preparation method of the external-use medicine for treating the damp toxin infectious diseases.
A total of 11 patients with Kellgren-Lawrence grade II-III knee OA who were admitted to the outpatient clinic with knee pain and who had received conservative treatment for a period of 6 months and who had not benefited from it will be taken. Patients will be evaluated 7 (V1-7) during the study period. Patients who comply with the study criteria will be included in the study. The clinical, immunological and radiological efficacy of the treatment and clinical improvement will be evaluated in all follow-up patients at the beginning and at the beginning of the treatment.
This project will be conducted as a prospective before-and-after study at four major trauma centres in India, with the intervention occurring between pre- and post-intervention phases. Included in the study will be all patients presenting to any of the four trauma hospitals with a potentially life-threatening or limb-threatening injury. The intervention will be the introduction of a structured Trauma Quality Improvement Meeting (TQIM), using a checklist and training program. The primary outcome will be compliance with the TQIM checklist, measured as the proportion of discussed cases (trauma deaths) for which problems with care, preventability and corrective actions were discussed and / or agreed. The secondary outcomes will include in-hospital risk-adjusted mortality, hospital length of stay and time to emergency surgery. Data collection will occur at all meetings at the four trauma hospitals at which trauma deaths are discussed. Data will also be collected in a dedicated trauma registry.
Autoimmune polyglandular syndromes (APS) are classified into four main categories, APS1-APS4. APS1 is caused by AIRE gene loss of function mutations, while the genetic background of the other APS remains to be clarified. Here, we investigated the potential association between AIRE gene promoter Single Nucleotide Polymorphisms (SNPs) and susceptibility to APS. We sequenced the AIRE gene promoter of 74 APS patients, also analyzing their clinical and autoantibody profile, and we further conducted molecular modeling studies on the identified SNPs. Overall, we found 6 SNPs (-230Y, -655R, -261M, -380S, -191M, -402S) of the AIRE promoter in patients' DNA. Interestingly, folding free energy calculations highlighted that all identified SNPs, except for -261M, modify the stability of the nucleic acid structure. A rather similar percentage of APS3 and APS4 patients had polymorphisms in the AIRE promoter. Conversely, there was no association between APS2 and AIRE promoter polymorphisms. Further AIRE promoter SNPs were found in 4 out of 5 patients with APS1 clinical diagnosis that did not harbor AIRE loss of function mutations. We hypothesize that AIRE promoter polymorphisms could contribute to APS predisposition, although this should be validated through genetic screening in larger patient cohorts and in vitro and in vivo functional studies.
The patients will be given Maitland mobilization (central glide on effected cervical spinous process) with McKenzie exercises. Grade i and ii mobilizations will be given in week 1 and then progressed to grade iii and iv in week 2. The total time duration will be 25-30 minutes. Participants will be given Hot pack for 15 minutes.
BACKGROUND: Emergency presentations make up a large proportion of a general surgeon's workload. Patients who have emergency surgery carry a higher rate of mortality and complications. We aim to review the impact of surgical subspecialization on patients following upper gastrointestinal (UGI) emergency surgery.
METHODS: A systematic search of Ovid Embase, Ovid MEDLINE, and Cochrane databases using a predefined search strategy was completed reviewing studies published from 1st of January 1990 to August 27, 2023. The study was prospectively registered with PROSPERO (CRD42022359326). Studies were reviewed for the following outcomes: 30-day mortality, in-hospital mortality, conversion to open, length of stay, return to theater, and readmission.
RESULTS: Of 5181 studies, 24 articles were selected for full text review. Of these, seven were eligible and included in this study. There was a statistically significant improvement in 30-day mortality favoring UGI specialists (OR 0.71 [95% CI 0.55-0.92 and p = 0.009]) and in-hospital mortality (OR 0.29 [95% CI 0.14-0.60 and p = 0009]). There was a high degree of study heterogeneity in 30-day mortality; however, a low degree of heterogeneity within in-hospital mortality. There was no statistical significance when considering conversion to open and insufficient data to allow meta-analysis for return to theater or readmission rates.
CONCLUSION: In emergency UGI surgery, there was improved 30-day and in-hospital mortality for UGI specialists. Therefore, surgeons should consider early involvement of a subspecialist team to improve patient outcomes.
A psyllium composition in tablet form is provided having a wetting agent, a disintegrant and a binding agent. In one embodiment, the wetting agent is polysorbate 80, the binding agent is polyvinyl pyrrolidone and the dry binding agent and disintegrant is microcrystalline cellulose. Calcium carbonate may also be added to serve as a disintegrant in HCL. The tablets are manufactured by mixing the psyllium powder with a solution of povidone and polysorbate 80. Microcrystalline cellulose may be added either during or after granulation. After mixing, the composition is compressed into tablet form. The mixing of the ingredients in specific quantities allows a tablet to be manufactured that is both resistant to fracture and at the same time disintegrates easily and quickly in the gastrointestinal tract of the patient.
The present invention relates to an anti-BCMA single domain antibody comprising CDR1, CDR2, CDR3 and framework region sequences; wherein, the CDR1 sequence is shown in SEQ ID NO.1 or SEQ ID NO. 4; the CDR2 sequence is shown in SEQ ID NO.2 or SEQ ID NO. 5; the CDR3 sequence is shown in SEQ ID NO.3 or SEQ ID NO. 6. The invention also relates to the related application of the single domain antibody for resisting BCMA and a preparation method thereof. The anti-BCMA single domain antibodies B1 and B65 have excellent affinity with antigen, can only bind with BCMA, can not bind with other antigens (CD38, CD138 and the like), have good specificity on the BCMA, can effectively bind with BCMA positive target cells by the single domain antibodies B1 and B65, provide theoretical basis for the drugs for treating diseases or symptoms related to the expression of the BCMA, and are particularly suitable for treating multiple myeloma.
To augment teaching data so as to enable the accuracy of natural language processing on medical text to be improved.SOLUTION: A medical information processing device pertaining to the present embodiment processes medical text data using a medical text processing model. The medical information processing device comprises a receipt unit, a determination unit, an identification unit and a generation unit. The receipt unit receives a medical text data portion. The determination unit determines: a template corresponding to the medical text data portion; a classification label associated with the template; and a first medical term included in the medical text data portion, on the basis of the medical text data. The identification unit identifies a second medical term which is different from the first medical term and associated with the first medical term. The generation unit inserts the second medical term into the template to generate composite text data, on the basis of the second medical term.SELECTED DRAWING: Figure 5
Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 cycles in the absence of disease progression or unacceptable toxicity.
SIMCOR should be taken as a single daily dose at bedtime, with a low fat snack. Patients not currently on niacin extended-release and patients currently on niacin products other than niacin extended-release should start SIMCOR at a single 500/20 mg tablet daily at bedtime. Patients already taking simvastatin 20-40 mg who need additional management of their lipid levels may be started on a SIMCOR dose of 500/40 mg once daily at bedtime. [See Warnings and Precautions (5.2)]. The dose of niacin extended-release should not be increased by more than 500 mg daily every 4 weeks - see Table 1. The recommended maintenance dose for SIMCOR is 1000/20 mg to 2000/40 mg (two 1000/20 mg tablets) once daily depending on patient tolerability and lipid levels. The efficacy and safety of doses of SIMCOR greater than 2000/40 mg daily have not been studied and are therefore not recommended. If SIMCOR therapy is discontinued for an extended period of time (> 7 days), re-titration as tolerated is recommended. SIMCOR tablets should be taken whole and should not be broken, crushed, or chewed before swallowing.

Due to the increased risk of hepatotoxicity with other modified-release (sustained-release or time-release) niacin preparations or immediate-release (crystalline) niacin, SIMCOR should only be substituted for equivalent doses of niacin extended-release (NIASPAN).

Flushing [See Adverse Reactions (6.1)] may be reduced in frequency or severity by pretreatment with aspirin up to the recommended dose of 325 mg (taken approximately 30 minutes prior to SIMCOR dose). Flushing, pruritus, and gastrointestinal distress are also reduced by gradually increasing the dose of niacin (refer to Table 1) and avoiding administration on an empty stomach. Concomitant alcoholic, hot drinks or spicy foods may increase the side effects of flushing and pruritus and should be avoided around the time of SIMCOR ingestion.